Should I buy or sell Revance Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks .

What is Revance Therapeutics' stock price target for 2024?

8 brokers have issued 12-month price objectives for Revance Therapeutics' stock. Their RVNC share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $13.75 in the next year. This suggests a possible upside of 262.8% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts .

How have RVNC shares performed in 2024?

Revance Therapeutics' stock was trading at $8.79 at the start of the year. Since then, RVNC shares have decreased by 56.9% and is now trading at $3.79. View the best growth stocks for 2024 here .

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 13,550,000 shares, an increase of 24.7% from the March 15th total of 10,870,000 shares. Based on an average trading volume of 1,810,000 shares, the days-to-cover ratio is currently 7.5 days. View Revance Therapeutics' Short Interest .

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RVNC earnings forecast .

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.17. The biopharmaceutical company earned $69.80 million during the quarter, compared to analysts' expectations of $64.02 million.

What ETFs hold Revance Therapeutics' stock?

ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com . Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS) , Exelixis (EXEL) , SCYNEXIS (SCYX) , AbbVie (ABBV) , Myovant Sciences (MYOV) , Nektar Therapeutics (NKTR) , Sorrento Therapeutics (SRNE) , Bausch Health Companies (BHC) , Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO) .

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.09%). Insiders that own company stock include Angus C Russell , Aubrey Rankin , Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie , Erica Jordan, Mark J Foley and Tobin Schilke. View institutional ownership trends .

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free RVNC Stock Alerts

$3.79

+0.03 (+0.80%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.63
▼
$3.82
50-Day Range: $3.76
▼
$7.14
52-Week Range: $3.63
▼
$37.98

Volume: 1.60 million shs
Average Volume: 1.79 million shs
Market Capitalization: $394.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.75

Get Revance Therapeutics alerts:

Revance Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 262.8% Upside
$13.75 Price Target
Short Interest: Bearish
13.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: 0.45
Based on 4 Articles This Week
Insider Trading: Selling Shares
$143,642 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.17) to ($1.13) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.30 out of 5 stars

Medical Sector

122nd out of 918 stocks

Pharmaceutical Preparations Industry

37th out of 402 stocks

4.3

Analyst's Opinion

Consensus Rating
Revance Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Revance Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
13.00% of the outstanding shares of Revance Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Revance Therapeutics has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Revance Therapeutics has recently increased by 24.66%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Revance Therapeutics does not currently pay a dividend.
Dividend Growth
Revance Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Revance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Revance Therapeutics is -0.88.

2.5

News and Social Media Coverage

News Sentiment
Revance Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Revance Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 8 people have searched for RVNC on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
MarketBeat Follows
8 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revance Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,642.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Revance Therapeutics is held by insiders.
Percentage Held by Institutions
97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Revance Therapeutics are expected to grow in the coming year, from ($2.17) to ($1.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revance Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revance Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Revance Therapeutics Stock (NASDAQ:RVNC)

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

RVNC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVNC Stock News Headlines

March 20, 2024 | insidertrades.com

Revance Therapeutics, Inc. (NASDAQ:RVNC) Insider Dwight Moxie Sells 8,125 Shares

April 12, 2024 | finance.yahoo.com

Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | businesswire.com

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

March 27, 2024 | finance.yahoo.com

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 16, 2024 | finance.yahoo.com

RVNC Apr 2024 5.000 put

March 11, 2024 | msn.com

Revance stock rises after CEO discloses share purchase

March 4, 2024 | markets.businessinsider.com

Revance Prices Offering Of 16 Mln Shares At $6.25/Share; Stock Drops

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 4, 2024 | marketwatch.com

Revance Therapeutics Shares Slide After Public Offering

March 4, 2024 | markets.businessinsider.com

Revance Proposes Public Offering Of $100 Mln Of Shares; Stock Down Over 8% In Pre-market

March 4, 2024 | msn.com

Revance Therapeutics down 7%, prices $100M share offering

March 4, 2024 | finance.yahoo.com

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

March 4, 2024 | businesswire.com

Revance Announces Proposed Public Offering of Common Stock

March 2, 2024 | finance.yahoo.com

US$16.33: That's What Analysts Think Revance Therapeutics, Inc. (NASDAQ:RVNC) Is Worth After Its Latest Results

March 2, 2024 | finance.yahoo.com

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

Revance Therapeutics Full Year 2023 Earnings: Beats Expectations

February 29, 2024 | seekingalpha.com

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

February 29, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)

February 29, 2024 | finance.yahoo.com

Q4 2023 Revance Therapeutics Inc Earnings Call

February 29, 2024 | markets.businessinsider.com

Revance Therapeutics: Strategic Pivot and Growth Potential Justify Buy Rating

February 28, 2024 | finance.yahoo.com

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

February 28, 2024 | finance.yahoo.com

Revance Therapeutics Inc (RVNC) Reports Strong Revenue Growth in Q4 and Full Year 2023

February 27, 2024 | benzinga.com

Earnings Outlook For Revance Therapeutics

February 22, 2024 | benzinga.com

Revance Therapeutics Stock (NASDAQ:RVNC), Short Interest Report

February 21, 2024 | finance.yahoo.com

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

February 21, 2024 | businesswire.com

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

See More Headlines

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RVNC
CUSIP: N/A
CIK: 1479290
Web: www.revance.com
Phone: (615) 724-7755
Fax: 510-742-3401
Employees: 597
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.75
High Stock Price Target: $20.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +262.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-323,990,000.00
Net Margins: -138.43%
Pretax Margin: -138.30%
Return on Equity: N/A
Return on Assets: -45.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.80
Quick Ratio: 3.29

Sales & Book Value

Annual Sales: $234.04 million
Price / Sales: 1.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.73) per share
Price / Book: -2.19

Miscellaneous

Outstanding Shares: 104,220,000
Free Float: 98,901,000
Market Cap: $394.99 million
Optionable: Optionable
Beta: 1.05

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Mark J. Foley (Age 59)
CEO & Director
Comp: $1.26M
Mr. Dustin S. Sjuts (Age 44)
President
Comp: $910.69k
Mr. Tobin C. Schilke (Age 49)
CFO & Principal Accounting Officer
Comp: $731.58k
Mr. Dwight O. Moxie (Age 48)
Chief Legal Officer & General Counsel
Comp: $713.82k
Jessica Serra
Head of Investor Relations & ESG
Ms. Jeanie D. Herbert
Senior Director of Investor Relations & Corporate Communications
Ms. Taryn Conway
Vice President of Marketing
Ms. Amie Krause
Chief People Officer
Dr. Conor Gallagher
Head of Medical Affairs & Aesthetics
Dr. David A. Hollander M.B.A. (Age 49)
M.D., Chief Medical Officer of Global Therapeutics Franchise Lead

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVNC Stock Analysis - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVNC shares.
View RVNC analyst ratings or view top-rated stocks.
What is Revance Therapeutics' stock price target for 2024?: 8 brokers have issued 12-month price objectives for Revance Therapeutics' stock. Their RVNC share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $13.75 in the next year. This suggests a possible upside of 262.8% from the stock's current price.
View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts.
How have RVNC shares performed in 2024?: Revance Therapeutics' stock was trading at $8.79 at the start of the year. Since then, RVNC shares have decreased by 56.9% and is now trading at $3.79.
View the best growth stocks for 2024 here.
Are investors shorting Revance Therapeutics?: Revance Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 13,550,000 shares, an increase of 24.7% from the March 15th total of 10,870,000 shares. Based on an average trading volume of 1,810,000 shares, the days-to-cover ratio is currently 7.5 days.
View Revance Therapeutics' Short Interest.
When is Revance Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RVNC earnings forecast.
How were Revance Therapeutics' earnings last quarter?: Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.17. The biopharmaceutical company earned $69.80 million during the quarter, compared to analysts' expectations of $64.02 million.

What ETFs hold Revance Therapeutics' stock?: ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).
What is Mark Foley's approval rating as Revance Therapeutics' CEO?: 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Revance Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).
Who are Revance Therapeutics' major shareholders?: Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.09%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Erica Jordan, Mark J Foley and Tobin Schilke.
View institutional ownership trends.
How do I buy shares of Revance Therapeutics?: Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVNC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial